Akari Therapeutics, Plc (AKTX)
| Market Cap | 17.71M -39.6% |
| Revenue (ttm) | n/a |
| Net Income | -30.96M |
| EPS | -23.94 |
| Shares Out | 2.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,879 |
| Open | 8.80 |
| Previous Close | 9.29 |
| Day's Range | 7.60 - 9.03 |
| 52-Week Range | 3.02 - 30.00 |
| Beta | 1.47 |
| Analysts | Strong Buy |
| Price Target | 25.50 (+229.03%) |
| Est. Earnings | Nov 16, 2026 |
About AKTX
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for AKTX stock is "Strong Buy." The 12-month stock price target is $25.5, which is an increase of 229.03% from the latest price.
News
Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit
Presentation to explore the potential of RNA-splicing payloads to drive broad anti-tumor effects through direct cell killing along with immune activation
Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
CEO Abizer Gaslightwala discusses Akari's novel PH1 payload strategy and execution priorities supporting AKTX-101's advancement toward planned Phase 1 clinical development in mid-2027
Akari Therapeutics appoints Vatnak Vat-Ho as chief business officer
Akari Therapeutics (AKTX) announced the appointment of Vatnak Vat-Ho as chief business officer. Most recently, Vat-Ho was chief business officer of Ryvu Therapeutics.
Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering
Mr. Vat-Ho's appointment adds more than 20 years of oncology, biopharma and capital markets experience, including senior roles in transactions totaling more than $25 billion in aggregate value
Akari Therapeutics expands IP portfolio with PCT filing for ADC payload
Akari Therapeutics (AKTX) announced the filing of PCT/US2026/45955, expanding the Company’s intellectual property portfolio around its novel splicing-modulating payload, PH1 and PH1-based ADCs.
Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
Patent filing covers PH1 payload's unique ability to disrupt multiple cancer-driving pathways in addition to its overall cytotoxic mechanism
Akari Therapeutics, Proxy statement: Proxy filing
Akari Therapeutics, filed a proxy statement on October 1, 2026, providing details for shareholder voting and corporate governance matters.
Akari price target adjusted at Alliance Global after transfer, reverse split
Alliance Global analyst Matthew Venezia raised the firm’s price target on Akari Therapeutics (AKTX) to $19.50 from $7 and keeps a Buy rating on the shares, citing a reverse split…
Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Video webcast now available here
Akari Therapeutics reports new AKTX-101 preclinical data
Akari Therapeutics (AKTX) announced new preclinical data demonstrating the potential of AKTX-101, the company’s proprietary TROP2-targeted ADC utilizing its novel PH1 RNA spliceosome modulating payloa...
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
AKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027
Akari Therapeutics, Quarterly report: Q2 2026
Akari Therapeutics, has published its Q2 2026 quarterly earnings report on August 13, 2026.
Akari Therapeutics, Earnings release: Q2 2026
Akari Therapeutics, released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation
Discussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's proprietary PH1 spliceosome-modulating payloa...
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity
Virtual Investor "What This Means" segment highlights strategic Whitehawk collaboration, accelerating industry validation of novel ADC payloads, and Akari's differentiated PH1 platform
Akari Therapeutics enters research collaboration with Whitehawk Therapeutics
Akari Therapeutics (AKTX) announced a strategic research collaboration with Whitehawk Therapeutics. Under the collaboration, the companies will conduct a series of focused preclinical studies evaluati...
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing m...
Maxim upgrades Akari Therapeutics to Buy on AKTX-101 data, ADC M&A
As previously reported, Maxim upgraded Akari Therapeutics (AKTX) to Buy from Hold with a $30 price target. The firm attributes the upgrade to a combination of capital raised, preclinical data…
Akari Therapeutics upgraded to Buy from Hold at Maxim
Maxim upgraded Akari Therapeutics (AKTX) to Buy from Hold with a $30 price target
Akari Therapeutics, Registration statement: Registration filing
Akari Therapeutics, filed a registration statement on July 10, 2026, providing details about a securities offering with the SEC.
Akari Therapeutics, Registration statement: Registration filing
Akari Therapeutics, filed a registration statement on July 8, 2026, providing details about a securities offering with the SEC.
Akari Therapeutics (AKTX) Stock Rallies on a Scientific Advisory Board Addition
Akari Therapeutics stock rallied on Tuesday after the company added Patricia LoRusso to its Scientific Advisory Board.
Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board
Globally recognized leader in early-phase oncology clinical development and experimental therapeutics Strengthens strategic expertise as Akari advances its novel ADC payload that modulates RNA splicin...